Segmental jumping translocation in leukemia and lymphoma with a highly complex karyotype

Leukemia & Lymphoma
K Tanaka, N Kamada

Abstract

In order to identify the oncogene associated with malignant transformation 141 leukemia and malignant lymphoma patients were studied by FISH. Specific chromosome regions were translocated onto structurally abnormal chromosomes, resulting in partial tri-, tetra-, or pentasomy of these regions. We designated this type of chromosomal translocation as a "segmental jumping translocation (SJT)". These SJTs were found in several chromosomal regions such as 8q24, 9q34, 11q13, 11q23, 13q14, 14q24-q32, 21q22 and 22q11. The SJT at 9q34, which involved the ABL oncogene, was found in three of nine secondary leukemia patients who were treated with anticancer drugs and radiation. Non-Hodgkin's lymphoma and acute myeloid leukemia (AML) patients had 3-7 copies of SJT at 11q13 or 11q23. SJT at 14q32 and 21q22 were predominantly detected in the acute type of adult T-cell leukemia (8 of 27 patients) and in AML (5 of 17 patients). The size of the SJT regions varied among the patients. The overlapping region within the SJT could involve oncogene(s) associated with transformation to the advanced stage in leukemia and lymphoma patients. The SJT provides evidence of a new mechanism for gene amplification and formation of unidentified marker chromosomes...Continue Reading

References

Jan 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·G Kovacs, H F Kung
Feb 1, 1991·Cancer Genetics and Cytogenetics·M D ReisJ S Senn
Apr 1, 1990·The American Journal of Occupational Therapy : Official Publication of the American Occupational Therapy Association·M Mody, J Nagai
Jul 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·D D Von HoffG M Wahl
May 1, 1983·American Journal of Clinical Pathology·J W VardimanJ Rowley
Mar 1, 1995·Genes, Chromosomes & Cancer·M BentzP Lichter
Mar 1, 1995·Cancer Genetics and Cytogenetics·L SeghezziE Maserati
Sep 1, 1994·Cancer Genetics and Cytogenetics·I WlodarskaH Van Den Berghe
Oct 25, 1994·Proceedings of the National Academy of Sciences of the United States of America·W P Stemmer
Nov 1, 1993·Cancer Genetics and Cytogenetics·T ShikanoY Ishikawa

❮ Previous
Next ❯

Citations

May 30, 2002·Cancer Genetics and Cytogenetics·Michelle DolanBetsy Hirsch
Jul 31, 2001·Genes, Chromosomes & Cancer·C FonatschK Lechner
May 18, 2010·Cancer Genetics and Cytogenetics·Iveta SárováKyra Michalová
Jul 9, 2003·Immunological Reviews·Kevin D MillsFrederick W Alt
Apr 21, 2007·Genes, Chromosomes & Cancer·Roland Berger, Olivier A Bernard

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

22q11 Deletion Syndrome

22q11.2 deletion syndrome, also known as DiGeorge syndrome, is a congenital disorder caused by a partial deletion of chromosome 22. Symptoms include heart defects, poor immune system function, a cleft palate, complications related to low levels of calcium in the blood, and delayed development. Discover the latest research on this disease here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.